EDSA is trading 6.5% up at $7.68 following recent funding and clinical data momentum, outperforming a broadly weaker U.S. market despite a lack of fresh company-specific headlines today.
- Sentiment remains supported by a $3.5 million private placement led by the CEO and healthcare-focused investors on June 11, 2026.
- Recent positive exploratory data for paridiprubart in Acute Respiratory Distress Syndrome (ARDS) continues to provide a tailwind for the stock.